Cognito Therapeutics presented new biomarker data from its Phase 2 study at the Alzheimer's Association International Conference. The findings show that daily use of Spectris, its non-invasive sensory stimulation headset, increased cerebrospinal fluid levels of several HDL-like lipid transport proteins in patients with amyloid-positive mild cognitive impairment. The company reads the data as a coordinated biological response. The data are exploratory but reinforce a proposed mechanism for the gamma-frequency approach. A full data readout is expected next month.